Radiation Dose-Volume Effects in the Lung

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 3 SUPPL., 2010, Pages

  Marks, Lawrence B ^a   Bentzen, Soren M ^b   Deasy, Joseph O ^c   Bradley, Jeffrey D ^c   Vogelius, Ivan S ^b   El Naqa, Issam ^c   Hubbs, Jessica L ^a   Lebesque, Joos V ^e   Timmerman, Robert D ^f   Martel, Mary K ^g   Jackson, Andrew ^h  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c USA   (United States)

^d Spring)   (United States)

^e ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^h MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Lung injury; Pneumonitis; QUANTEC; Radiation

Indexed keywords

DOSE-VOLUME; DOSIMETRIC PARAMETER; FRACTIONATION EFFECTS; LUNG INJURY; RADIATION DOSE;

BIOLOGICAL ORGANS; DOSIMETRY;

RADIATION EFFECTS;

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; ETOPOSIDE; GEMCITABINE; PACLITAXEL;

ARTICLE; BIOLOGICAL MODEL; COMORBIDITY; DOSIMETRY; DYSPNEA; HUMAN; LUNG CANCER; LUNG INJURY; LUNG TOXICITY; LUNG TUMOR; LUNG VOLUME; MATHEMATICAL MODEL; PNEUMONIA; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION HAZARD; RADIATION INJURY; RADIATION PNEUMONIA; RADIATION RESPONSE; RISK FACTOR;

HUMANS; LUNG; LUNG NEOPLASMS; MODELS, BIOLOGICAL; MODELS, STATISTICAL; RADIATION PNEUMONITIS; RADIATION TOLERANCE; RADIOTHERAPY DOSAGE;

EID: 76449119210     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.06.091     Document Type: Article

References (67)

1. Mehta V. Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: Pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63 (2005) 5-24
2. Marks L.B., Yu X., Vujaskovic Z., et al. Radiation-induced lung injury. Semin Radiother Oncol 13 (2003) 333-345
3. Kocak Z., Evans E.S., Zhou S.M., et al. Challenges in defining radiation pneumonitis in patients with lung cancer. Int J Radiat Oncol Biol Phys 62 (2005) 635-638
4. Marks L.B., Hollis D., Munley M., et al. The role of lung perfusion imaging in predicting the direction of radiation-induced changes in pulmonary function tests. Cancer 88 (2000) 2135-2141
5. Rancati T., Wennberg B., Lind P., et al. Early clinical and radiological pulmonary complications following breast cancer radiation therapy: NTCP fit with four different models. Radiother Oncol 82 (2007) 308-316
6. Kwa S.L., Lebesque J.V., Theuws J.C., et al. Radiation pneumonitis as a function of mean lung dose: An analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 42 (1998) 1-9
7. Graham M.V., Purdy J.A., Emami B., et al. Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 45 (1999) 323-329
8. Yorke E.D., Jackson A., Rosenzweig K.E., et al. Dose-volume factors contributing to the incidence of radiation pneumonitis in non-small-cell lung cancer patients treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 54 (2002) 329-339
9. Seppenwoolde Y., De Jaeger K., Boersma L.J., et al. Regional differences in lung radiosensitivity after radiotherapy for non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 60 (2004) 748-758
10. Yorke E.D., Jackson A., Rosenzweig K.E., et al. Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 63 (2005) 672-682
11. Hope A.J., Lindsay P.E., El Naqa I., et al. Modeling radiation pneumonitis risk with clinical, dosimetric, and spatial parameters. Int J Radiat Oncol Biol Phys 65 (2006) 112-124
12. Bradley J.D., Hope A., El Naqa I., et al. A nomogram to predict radiation pneumonitis, derived from a combined analysis of RTOG 9311 and institutional data. Int J Radiat Oncol Biol Phys 69 (2007) 985-992
13. Meadors M., Floyd J., and Perry M.C. Pulmonary toxicity of chemotherapy. Semin Oncol 33 (2006) 98-105
14. Robnett T.J., Machtay M., Vines E.F., et al. Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 48 (2000) 89-94
15. Hernando M.L., Marks L.B., Bentel G.C., et al. Radiation-induced pulmonary toxicity: A dose-volume histogram analysis in 201 patients with lung cancer. Int J Radiat Oncol Biol Phys 51 (2001) 650-659
16. Kong F.M., Ten Haken R., Eisbruch A., et al. Non-small cell lung cancer therapy-related pulmonary toxicity: An update on radiation pneumonitis and fibrosis. Semin Oncol 32 (2005) S42-S54
17. Movsas B., Raffin T.A., Epstein A.H., et al. Pulmonary radiation injury. Chest 111 (1997) 1061-1076
18. Onishi H., Kuriyama K., Yamaguchi M., et al. Concurrent two-dimensional radiotherapy and weekly docetaxel in the treatment of stage III non-small cell lung cancer: A good local response but no good survival due to radiation pneumonitis. Lung Cancer 40 (2003) 79-84
19. Tsujino K., Hirota S., Kotani Y., et al. Radiation pneumonitis following concurrent accelerated hyperfractionated radiotherapy and chemotherapy for limited-stage smallcell lung cancer: Dose-volume histogram analysis and comparison with conventional chemoradiation. Int J Radiat Oncol Biol Phys 64 (2006) 1100-1105
20. Roach III M., Gandara D.R., Yuo H.S., et al. Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors. J Clin Oncol 13 (1995) 2606-2612
21. Bentzen S.M., Skoczylas J.Z., and Bernier J. Quantitative clinical radiobiology of early and late lung reactions. Int J Radiat Biol 76 (2000) 453-462
22. Lebesque J.V., and Keus R.B. The simultaneous boost technique: The concept of relative normalized total dose. Radiother Oncol 22 (1991) 45-55
23. Wheldon T.E., Deehan C., Wheldon E.G., et al. The linear-quadratic transformation of dose-volume histograms in fractionated radiotherapy. Radiother Oncol 46 (1998) 285-295
24. Fryer C.J., Fitzpatrick P.J., Rider W.D., et al. Radiation pneumonitis: Experience following a large single dose of radiation. Int J Radiat Oncol Biol Phys 4 (1978) 931-936
25. Ozsahin M., Belkacémi Y., Pène Fo, et al. Interstitial pneumonitis following autologous bone-marrow transplantation conditioned with cyclophosphamide and total-body irradiation. Int J Radiat Oncol Biol Phys 34 (1996) 71-77
26. Sampath S., Schultheiss T.E., and Wong J. Dose response and factors related to interstitial pneumonitis after bone marrow transplant. Int J Radiat Oncol Biol Phys 63 (2005) 876-884
27. Timmerman R.D., Park C., and Kavanagh B.D. The North American experience with stereotactic body radiation therapy in non-small cell lung cancer. J Thorac Oncol 2 (2007) S101-S112
28. Timmerman R., Galvin J., Michalski J., et al. Accreditation and quality assurance for Radiation Therapy Oncology Group: Multicenter clinical trials using stereotactic body radiation therapy in lung cancer. Acta Oncol 45 (2006) 779-786
29. Timmerman R., Papiez L., McGarry R., et al. Extracranial stereotactic radioablation: Results of a phase I study in medically inoperable stage I non-small cell lung cancer. Chest 124 (2003) 1946-1955
30. Hara R., Itami J., Komiyama T., et al. Serum levels of KL-6 for predicting the occurrence of radiation pneumonitis after stereotactic radiotherapy for lung tumors. Chest 125 (2004) 340-344
31. Yamashita H., Nakagawa K., Nakamura N., et al. Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors. Radiat Oncol 2 (2007) 21
32. Miller K.L., Shafman T.D., Anscher M.S., et al. Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?. Int J Radiat Oncol Biol Phys 61 (2005) 64-69
33. Yom S.S., Liao Z., Liu H.H., et al. Initial evaluation of treatment-related pneumonitis in advanced-stage non-small-cell lung cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 68 (2007) 94-102
34. Sura S., Gupta V., Yorke E., et al. Intensity-modulated radiation therapy (IMRT) for inoperable non-small cell lung cancer: The Memorial Sloan-Kettering Cancer Center (MSKCC) experience. Radiother Oncol 87 (2008) 17-23
35. Allen A.M., Czerminska M., Jänne P.A., et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys 65 (2006) 640-645
36. Rice D.C., Smythe W.R., Liao Z., et al. Dose-dependent pulmonary toxicity after postoperative intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 69 (2007) 350-357
37. Miles E.F., Larrier N.A., Kelsey C.R., et al. Intensity-modulated radiotherapy for resected mesothelioma: The Duke experience. Int J Radiat Oncol Biol Phys 71 (2008) 1143-1150
38. Novakova-Jiresova A., van Luijk P., van Goor H., et al. Pulmonary radiation injury: Identification of risk factors associated with regional hypersensitivity. Cancer Res 65 (2005) 3568-3576
39. van Luijk P., Novakova-Jiresova A., Faber H., et al. Radiation damage to the heart enhances early radiation-induced lung function loss. Cancer Res 65 (2005) 6509-6511
40. Wiegman E.M., Meertens H., Konings A.W.T., et al. Loco-regional differences in pulmonary function and density after partial rat lung irradiation. Radiother Oncol 69 (2003) 11-19
41. Komaki R., Lee J.S., Milas L., et al. Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58 (2004) 1369-1377
42. Antonadou D., Coliarakis N., Synodinou M., et al. Randomized phase III trial of radiation treatment ± amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 51 (2001) 915-922
43. Antonadou D., Throuvalas N., Petridis A., et al. Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 57 (2003) 402-408
44. Movsas B., Scott C., Langer C., et al. Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation Therapy Oncology Group trial 98-01. J Clin Oncol 23 (2005) 2145-2154
45. Ozturk B., Egehan I., Atavci S., et al. Pentoxifylline in prevention of radiation-induced lung toxicity in patients with breast and lung cancer: A double-blind randomized trial. Int J Radiat Oncol Biol Phys 58 (2004) 213-219
46. Fu X.-L., Huang H., Bentel G., et al. Predicting the risk of symptomatic radiation-induced lung injury using both the physical and biologic parameters V30 and transforming growth factor [beta]. Int J Radiat Oncol Biol Phys 50 (2001) 899-908
47. Moiseenko V., Deasy J.O., and Dyk J.V. Radiobiological modeling for treatment planning. In: Van Dyk J. (Ed). The modern technology of radiation oncology: A compendium for medical physicists and radiation oncologists. Vol. 2 (2005), Medical Physics, Madison, WI
48. Seppenwoolde Y., Lebesque J.V., de Jaeger K., et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability. Int J Radiat Oncol Biol Phys 55 (2003) 724-735
49. Tucker S.L., Liu H.H., Wang S., et al. Dose-volume modeling of the risk of postoperative pulmonary complications among esophageal cancer patients treated with concurrent chemoradiotherapy followed by surgery. Int J Radiat Oncol Biol Phys 66 (2006) 754-761
50. Kong F.M., Hayman J.A., Griffith K.A., et al. Final toxicity results of a radiation-dose escalation study in patients with non-small-cell lung cancer (NSCLC): Predictors for radiation pneumonitis and fibrosis. Int J Radiat Oncol Biol Phys 65 (2006) 1075-1086
51. Wang S., Liao Z., Wei X., et al. Analysis of clinical and dosimetric factors associated with treatment-related pneumonitis (TRP) in patients with non-small-cell lung cancer (NSCLC) treated with concurrent chemotherapy and three-dimensional conformal radiotherapy (3D-CRT). Int J Radiat Oncol Biol Phys 66 (2006) 1399-1407
52. Martel M.K., Ten Haken R.K., Hazuka M.B., et al. Dose-volume histogram and 3-D treatment planning evaluation of patients with pneumonitis. Int J Radiat Oncol Biol Phys 28 (1994) 575-581
53. Kwa S.L., Theuws J.C., Wagenaar A., et al. Evaluation of two dose-volume histogram reduction models for the prediction of radiation pneumonitis. Radiother Oncol 48 (1998) 61-69
54. Oetzel D., Schraube P., Hensley F., et al. Estimation of pneumonitis risk in three-dimensional treatment planning using dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 33 (1995) 455-460
55. Rancati T., Ceresoli G.L., Gagliardi G., et al. Factors predicting radiation pneumonitis in lung cancer patients: A retrospective study. Radiother Oncol 67 (2003) 275-283
56. Kim T.H., Cho K.H., Pyo H.R., et al. Dose-volumetric parameters for predicting severe radiation pneumonitis after three-dimensional conformal radiation therapy for lung cancer. Radiology 235 (2005) 208-215
57. Willner J., Jost A., Baier K., et al. A little to a lot or a lot to a little? An analysis of pneumonitis risk from dose-volume histogram parameters of the lung in patients with lung cancer treated with 3-D conformal radiotherapy. Strahlenther Onkol 179 (2003) 548-556
58. Tsujino K., Hirota S., Endo M., et al. Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 55 (2003) 110-115
59. Armstrong J.G., Zelefsky M.J., Leibel S.A., et al. Strategy for dose escalation using 3-dimensional conformal radiation therapy for lung cancer. Ann Oncol 6 (1995) 693-697
60. Schallenkamp J.M., Miller R.C., Brinkmann D.H., et al. Incidence of radiation pneumonitis after thoracic irradiation: Dose-volume correlates. Int J Radiat Oncol Biol Phys 67 (2007) 410-416
61. Newton K.A. Total thoracic irradiation combined with intravenous injection of autogenous marrow. Clin Radiol 11 (1960) 14-21
62. Newton K.A., and Spittle M.F. An analysis of 40 cases treated by total thoracic irradiation. Clin Radiol 20 (1969) 19-22
63. Salazar O.M., Rubin P., Keller B., et al. Systemic (half-body) radiation therapy: Response and toxicity. Int J Radiat Oncol Biol Phys 4 (1978) 937-950
64. Van Dyk J., Keane T.J., and Kan S. Radiation pneumonitis following large single dose irradiation: A re-evaluation based on absolute dose to lung. Int J Radiat Oncol Biol Phys 7 (1981) 461-467
65. Rab G.T., Ivins J.C., Childs J., Donald S., et al. Elective whole lung irradiation in the treatment of osteogenic sarcoma. Cancer 38 (1976) 939-942
66. Breur K., Cohen P., Schweisguth O., et al. Irradiation of the lungs as an adjuvant therapy in the treatment of osteosarcoma of the limbs. An E.O.R.T.C. randomized study. European Journal of Cancer 14 (1978) 461-471
67. Burgers J.M., van Glabbeke V., Busson A., et al. Osteosarcoma of the limbs. Report of the EORTC-SIOP 03 trial 20781 investigating the value of adjuvant treatment with chemotherapy and/or prophylactic lung irradiation. Cancer 61 (1988) 1024-1031